Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
Adult
Allografts
Chromosomal Proteins, Non-Histone
/ genetics
Chromosomes, Human, Pair 6
/ genetics
Chromosomes, Human, Pair 9
/ genetics
Cord Blood Stem Cell Transplantation
Disease-Free Survival
Female
Gene Duplication
Graft vs Host Disease
/ etiology
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid, Acute
/ genetics
Male
Middle Aged
Nuclear Pore Complex Proteins
/ genetics
Oncogene Proteins
/ genetics
Oncogene Proteins, Fusion
/ genetics
Peripheral Blood Stem Cell Transplantation
Poly-ADP-Ribose Binding Proteins
/ genetics
Proportional Hazards Models
Remission Induction
Translocation, Genetic
Treatment Outcome
fms-Like Tyrosine Kinase 3
/ genetics
AML
DEK-NUP214
allo-SCT
prognosis
t(6;9) AML
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
02
09
2019
accepted:
19
11
2019
pubmed:
6
2
2020
medline:
28
1
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0·001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.
Substances chimiques
Chromosomal Proteins, Non-Histone
0
DEK protein, human
0
NUP214 protein, human
0
Nuclear Pore Complex Proteins
0
Oncogene Proteins
0
Oncogene Proteins, Fusion
0
Poly-ADP-Ribose Binding Proteins
0
FLT3 protein, human
EC 2.7.10.1
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
920-925Subventions
Organisme : Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III (ISCIII)
ID : PI16/01027
Organisme : Generalitat de Catalunya
ID : SLT002/16/00433
Organisme : SGR
ID : 1655
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Brunet, S., Labopin, M., Esteve, J., Cornelissen, J., Socié, G., Iori, A.P., Verdonck, L.F., Volin, L., Gratwohl, A. & Sierra, J. (2012) Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. Journal of Clinical Oncology, 30, 735-741.
Grimwade, D., Hills, R.K., Moorman, A.V., Walker, H., Chatters, S., Goldstone, A.H., Wheatley, K., Harrison, C.J. & Burnett, A.K. (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood, 116, 354-365.
Halaburda, K., Labopin, M., Houhou, M., Niederwieser, D., Finke, J., Volin, L., Maertens, J., Cornelissen, J.J., Milpied, N. & Stuhler, G. (2018) AlloHSCT for inv (3)(q21; q26)/t (3; 3)(q21; q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplantation, 53, 683-691.
Ishiyama, K., Takami, A., Kanda, Y., Nakao, S., Hidaka, M., Maeda, T., Naoe, T., Taniguchi, S., Kawa, K. & Nagamura, T. (2012a) Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t (6; 9)(p23; q34) dramatically improves the patient prognosis: a matched-pair analysis. Leukemia, 26, 461.
Ishiyama, K., Takami, A., Kanda, Y., Nakao, S., Hidaka, M., Maeda, T., Naoe, T., Taniguchi, S., Kawa, K. & Nagamura, T. (2012b) Prognostic factors for acute myeloid leukemia patients with t (6; 9)(p23; q34) who underwent an allogeneic hematopoietic stem cell transplant. Leukemia, 26, 1416.
Oyarzo, M.P., Lin, P., Glassman, A., Bueso-Ramos, C.E., Luthra, R. & Medeiros, L.J. (2004) Acute myeloid leukemia with t (6; 9)(p23; q34) is associated with dysplasia and a high frequency of flt3 gene mutations. American Journal of Clinical Pathology, 122, 348-358.
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V.I., Paschka, P., Roberts, N.D., Potter, N.E., Heuser, M., Thol, F. & Bolli, N. (2016) Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine, 374, 2209-2221.
Poiré, X., Labopin, M.,Maertens, J., Yakoub-Agha, I., Blaise, D., Ifrah, N., Socié, G., Gedde-Dhal, T., Schaap, N., Cornelissen, J.J., Vigouroux, S., Sanz, J., Michaux, L., Esteve, J., Mohty, M., & Nagler, A. (2017a) Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Journal of Hematology & Oncology, 10, 20-29.
Poiré, X., Labopin, M., Polge, E., Passweg, J., Craddock, C., Blaise, D., Cornelissen, J.J., Volin, L., Russell, N.H. & Socié, G. (2017b) Allogeneic stem cell transplantation benefits for patients≥ 60 years with acute myeloid leukemia and FLT3-ITD; a study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Haematologica, 103, 256-265.
Ruggeri, A., Labopin, M., Ciceri, F., Mohty, M. & Nagler, A. (2016) Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplantation, 51, 610.
Sandahl, J.D., Coenen, E.A., Forestier, E., Harbott, J., Johansson, B., Kerndrup, G., Adachi, S., Auvrignon, A., Beverloo, H.B. & Cayuela, J.-M. (2014) t (6; 9)(p22; q34)/DEK-NUP214 rearranged pediatric myeloid leukemia: an international study on 62 patients. Haematologica, 99, 865-872.
Slovak, M., Gundacker, H., Bloomfield, C., Dewald, G., Appelbaum, F., Larson, R., Tallman, M., Bennett, J., Stirewalt, D. & Meshinchi, S. (2006) A retrospective study of 69 patients with t (6; 9)(p23; q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies. Leukemia, 20, 1295.
Tarlock, K., Alonzo, T.A., Moraleda, P.P., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Ravindranath, Y., Lange, B., Woods, W.G. & Gamis, A.S. (2014) Acute myeloid leukaemia (AML) with t (6; 9)(p23; q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. British Journal of Haematology, 166, 254-259.
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M. & Neubauer, A. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA (abstract 2334). Blood, 99, 4326-4335.
Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E. & Tefferi, A. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.